The checkpoint inhibitor pembrolizumab (Keytruda) was well tolerated and demonstrated results in patients with PD-L1–positive, advanced esophageal tumors in the Merck-sponsored phase IB KEYNOTE-028 trial.
Pembrolizumab Promising in Advanced Esophageal Cancer